GGrantIndex
← Leaderboards

Catherine Orrell

New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc

$5,255,737
Attributed
$11,569,702
Total exposure
6
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY201625
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,569,702 · 6

By mechanism

R01$10,648,117 · 4
R34$617,179 · 1
R21$304,406 · 1

Most similar at New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc

Same institution · by research overlap

Others in their field

Top investigators on “South Africa

Research focus

South AfricaAntiretroviral TherapyAdherenceParticipantViralPharmacy FacilityTreatment AdherenceCaringViral Load ResultDesignSuccessInnovationFollow-UpClinicCompliance BehaviorMonitorProviderFutureSamplingTechnologySouth AfricanSecondary OutcomeHigh RiskInterview

Grant awards (24)

The SUSTAIN 2 study - SUStained HIV Treatment for Adherence After Interruption in Care$449,181
R01 · FY2025 · MH
Supporting Sustained HIVTreatment Adherence after Initiation (SUSTAIN)$392,957
R01 · FY2025 · MH
The SUSTAIN 2 study - SUStained HIV Treatment for Adherence After Interruption in Care$260,740
R01 · FY2025 · MH
Supporting Sustained HIVTreatment Adherence after Initiation (SUSTAIN)$159,336
R01 · FY2025 · MH
The SUSTAIN 2 study - SUStained HIV Treatment for Adherence After Interruption in Care$780,447
R01 · FY2024 · MH
Supporting Sustained HIVTreatment Adherence after Initiation (SUSTAIN)$534,950
R01 · FY2024 · MH
Urine tenofovir point-of-care test to identify patients in need of ART adherence support$326,142
R01 · FY2024 · AI
Designing Next Generation Treatment Strategies for Adolescents and Young Adults Living with HIV (The NextGen Study)$210,761
R34 · FY2024 · MH
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke$138,481
R21 · FY2024 · TW
Supporting Sustained HIVTreatment Adherence after Initiation (SUSTAIN)$532,562
R01 · FY2023 · MH
Urine tenofovir point-of-care test to identify patients in need of ART adherence support$331,897
R01 · FY2023 · AI
Designing Next Generation Treatment Strategies for Adolescents and Young Adults Living with HIV (The NextGen Study)$224,364
R34 · FY2023 · MH
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke$165,925
R21 · FY2023 · TW
Supporting Sustained HIVTreatment Adherence after Initiation (SUSTAIN)$560,193
R01 · FY2022 · MH
Urine tenofovir point-of-care test to identify patients in need of ART adherence support$338,904
R01 · FY2022 · AI
Designing Next Generation Treatment Strategies for Adolescents and Young Adults Living with HIV (The NextGen Study)$182,054
R34 · FY2022 · MH
Supporting Sustained HIVTreatment Adherence after Initiation (SUSTAIN)$687,050
R01 · FY2021 · MH
Urine tenofovir point-of-care test to identify patients in need of ART adherence support$343,910
R01 · FY2021 · AI
Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South Africa$749,372
R01 · FY2020 · AI
Urine tenofovir point-of-care test to identify patients in need of ART adherence support$343,464
R01 · FY2020 · AI
Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South Africa$865,505
R01 · FY2019 · AI
Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South Africa$1,099,420
R01 · FY2018 · AI
Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South Africa$1,077,794
R01 · FY2017 · AI
Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South Africa$814,293
R01 · FY2016 · AI